Lung Cancer – LCS & IPN
Median’s portfolio for Lung Cancer Diagnosis:
Lack of diagnostic accuracy is a major hurdle for screening program implementation and adherence
Lung cancer prognosis is the poorest of all common cancers, largely due to a high proportion of cases being detected at an advanced stage
A stage shift in lung cancer diagnosis would have a dramatic impact on lowering overall mortality
Median’s eyonis™ LCS
Unrivalled AI/ML Software as Medical Device (SaMD) enabling early lung cancer diagnosis with unprecedented performance
End-to-end AI/ML tech-based CADe CADx for early diagnosis in lung cancer screening programs
Indicated for the detection, localization, and characterization of pulmonary nodules into suspicious/malignant
Unprecedented sensitivity and specificity versus standard of care
A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician”. A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease”. Source: FDA
Additional indications
Liver cancer
Very early hepatocellular carcinoma (HCC)
About eyonis™
Early diagnosis & treatment of cancer
Latest news
PRESS RELEASE
Median Technologies Announces Rebranding of iBiopsy®, Changes Name to eyonis™
Median Technologies unveils a new identity, including a new name, logo, tagline for its iBiopsy® AI/ML tech-based suite of software as medical devices (SaMD) and business unit, as part of an extensive rebranding initiative. iBiopsy® becomes eyonis™.
PRESS RELEASE
Median Technologies to speak at the Radiological Society of North America 2023 Annual Meeting, Nov. 26 – 30, Chicago, IL, USA
AI Theater Presentation: “Transforming Cancer Diagnosis through End-to-End AI-Powered SaMD”